Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Chelation Therapy (TACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for Participants:~* Heart attack at least 6 weeks prior to study start~Exclusion Criteria for Participants:~* Serum creatinie level greater than 2.0 mg/dL~* Platelet count less than 100,000/µL~* Blood pressure greater than 160/100~* Chelation therapy within 5 years prior to study start~* History of allergic reactions to EDTA or any of the therapy's components~* Coronary or carotid revascularization procedures within 6 months prior to study start or a scheduled revascularization~* Cigarette smoking within 3 months prior to study start~* Childbearing potential~* History of liver disease~* Active heart failure or heart failure hospitalization within 6 months.~* Diagnoses of additional medical conditions that could otherwise limit patient survival~* Inability to tolerate 500-mL infusions weekly.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EDTA + high dose vitamin (Type: ACTIVE_COMPARATOR): Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
- EDTA + high dose vitamin placebo (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
- EDTA placebo + high dose vitamin (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
- EDTA placebo + high dose vitamin placebo (Type: PLACEBO_COMPARATOR): Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Based on this trial design, predict the completion outcome and termination type (if applicable).